Celltrion Pharm Posts Record Quarterly Revenue and Operating Profit in Q3
Revenue and operating profit rise 17.2% and 48.4% year on year, respectively; operating margin at 14.8%
Cumulative operating profit reaches 56.1 billion won in the first three quarters, surpassing last year's full-year total
Celltrion Pharm said in an earnings disclosure on November 9 that it recorded revenue of 161.9 billion won and operating profit of 23.9 billion won in the third quarter of 2026. These figures were up 17.2% and 48.4%, respectively, from the same period a year earlier, and marked the highest quarterly results on record for both revenue and operating profit. Operating profit reached a new quarterly high for the second consecutive quarter, following the second quarter.
The operating margin in the third quarter was 14.8%, up 3.1 percentage points from the same period a year earlier. Stable sales of chemical drugs, expanded prescriptions for biologics at major hospitals, and higher utilization of the prefilled syringe (PFS) production facility drove the results. A lower cost-to-revenue ratio also contributed to improved profitability.
Cumulative revenue for the first three quarters was 447.3 billion won, up 17.1% from the same period a year earlier, while operating profit rose 32.4% to 56.1 billion won. Cumulative operating profit surpassed the full-year total for last year in just nine months.
By business segment, revenue from chemical drugs was 68.4 billion won. Godex, the company's flagship treatment for liver disease, generated revenue of 17.7 billion won, up 10.3% from the same period a year earlier, while Dilatrend, a hypertension treatment, posted revenue of 15.8 billion won, up 5.5%. Amlozet, a combination treatment for hypertension and hyperlipidemia, recorded revenue of 600 million won, an increase of 355.9%, driven by expanded prescriptions.
Revenue from biologics was 45.2 billion won, up 40.2% from the same period a year earlier. The increase was driven by securing new prescribing hospitals and expanding sales at existing ones. Remsima, a treatment for autoimmune diseases, generated revenue of 14.9 billion won, up 18.8%, helped by approval to increase the dosage of its pen-type product. Yuflyma posted revenue of 2.9 billion won, up 54.1%. The cancer treatments Herzuma and Truxima recorded revenue of 5.1 billion won and 4.1 billion won, up 17.8% and 64.0%, respectively, while Vegzelma generated 3.6 billion won, up 9.4%.
New product lines launched in South Korea last year also continued to grow. Stoboclo, a treatment for bone diseases, generated revenue of 7.7 billion won, up 64.5% from the same period a year earlier. Eydenzelt, a treatment for eye diseases, posted revenue of 4.1 billion won, up 149.1%, while Omlyclo, a treatment for allergic diseases, recorded revenue of 1.7 billion won, up 64.8%. Steqeyma and Aptozma, both treatments for autoimmune diseases, each generated revenue of 500 million won.
Revenue from contract manufacturing rose 26.2% from the same period a year earlier to 48.2 billion won. In particular, the PFS production facility operated at full capacity, driving a 44.2% increase in related commercial production revenue to 40.4 billion won.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Celltrion Pharm representative said, "Robust sales of our flagship products, expanded prescriptions for biologics, and strong contract manufacturing performance at our PFS facility combined to deliver record quarterly revenue and operating profit." The representative added, "We will carry the growth momentum across our business segments through the end of the year and work to achieve meaningful results for the full year."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.